Bayer AG

As of June 30, 2026, Bayer A.G. carries a market capitalization of 54.03B, placing it among publicly traded companies globally. Its enterprise value stands at 48.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bayer A.G.'s next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Bayer A.G. has 982.42M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.04, and the price-to-book ratio stands at 1.60.

As of June 30, 2026, Bayer A.G. trades at an EV/EBITDA multiple of 3.56 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.93 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.19 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 48.37B versus a market cap of 54.03B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bayer A.G. maintains a current ratio of 1.04, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Bayer A.G. posted a negative return on equity (ROE) of -5.80, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.64, reflecting losses generated across the asset base. The company generates approximately 580,753.56 in revenue per employee across its workforce of 89,262.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.54 indicates how many times Bayer A.G. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bayer A.G. recorded 559.81M in income tax expense. The company reported a pretax loss of -1.40B and -1.99B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 20, 2026, Bayer A.G.'s stock has gained approximately 54.58% over the past 52 weeks. The 50-day moving average sits at 54.69, while the 200-day moving average is 45.72.

Over the twelve months ended June 30, 2026, Bayer A.G. generated 51.84B in revenue and converted that into -1.99B in net income, yielding earnings per share of -1.99. EBITDA reached 13.60B, while operating income came in at 9.32B.

These figures are as of June 30, 2026. Total book value stands at 33.80B, with working capital of 1.57B providing operational flexibility.

Bayer A.G. produced 5.46B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.09B in capital expenditures, free cash flow totaled 2.37B - equivalent to 2.42 per share.

Over the twelve months ended June 30, 2026, Bayer A.G. posted a gross margin of 59.05, reflecting its pricing power and cost economics. The operating margin of 17.98 and net profit margin of -3.83 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Bayer A.G. paid dividends of 0.15 per share. The dividend payout ratio of -7.76 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.39, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.58, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bayer A.G. shareholders.

Bayer A.G.'s most recent stock split took place on June 6, 2018.